EFCCA Magazine 2/2023
Our latest issue of the EFCCA magazine is out!!!
You will find updates on our activities, news from our members and partners, experiences of living with IBD and ongoing medical research.
Happy reading!
Our latest issue of the EFCCA magazine is out!!!
You will find updates on our activities, news from our members and partners, experiences of living with IBD and ongoing medical research.
Happy reading!
EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD.
November, 2022
The study developed a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Other indicators include, for example, clinical, endoscopic, and biomarker remission, fatigue, and urgency to go to the toilet.
We take great pleasure in informing you that EFCCA is one of the 12 partners coming from 9 countries of the consortium for the miGut-Health Project, which has been selected for European funding under the Horizon 2020 framework. This project will strive to empower people living with IBD by creating state-of-the-art strategies for early disease prediction, prevention, and health monitoring. This will be achieved through data-driven approaches, personalised preventive interventions (such as nutritional changes), and innovative eHealth solutions.
READ MORE
IBD HAS NO AGE is an EFCCA campaign started in 2022 in order to raise awareness of how Inflammatory Bowel Disease (IBD) is impacting on the life of people aged 60 years and over. This year, for World IBD Day 2023 (19 May), we will launch a survey on people with IBD aged 60 years and over to investigate more on this topic with questions related to both quality of care and quality of life.
The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated.
The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention.
The GENEGUT project will transform the treatment of ileal CD by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects.